Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Telix Pharmaceuticals ( (AU:TLX) ).
Telix Pharmaceuticals reported a significant 63% year-over-year increase in revenue for Q2 2025, reaching approximately $204 million. The company reaffirmed its FY 2025 revenue guidance of $770 million to $800 million. Key developments include the U.S. launch of Gozellix®, which has been assigned a Level II HCPCS code, and progress in the ProstACT™ Global Phase 3 trial with regulatory approvals for expansion into China, Japan, and Canada. These advancements highlight Telix’s strong market position and ongoing momentum in its therapeutic pipeline, despite competitive pricing pressures. The company’s strategic initiatives and regulatory achievements are expected to enhance its industry positioning and stakeholder value.
The most recent analyst rating on (AU:TLX) stock is a Buy with a A$31.00 price target. To see the full list of analyst forecasts on Telix Pharmaceuticals stock, see the AU:TLX Stock Forecast page.
More about Telix Pharmaceuticals
Telix Pharmaceuticals is a company operating in the biotechnology industry, focusing on the development and commercialization of diagnostic and therapeutic products using molecularly targeted radiation. Their primary products include radiopharmaceuticals for the diagnosis and treatment of cancer, with a market focus on precision medicine.
Average Trading Volume: 1,331,989
Technical Sentiment Signal: Strong Buy
Current Market Cap: A$8.55B
For detailed information about TLX stock, go to TipRanks’ Stock Analysis page.